Valuation: Caplin Point Laboratories Limited

Market Cap 187B 1.95B 1.71B 1.59B 1.46B 2.74B 2.78B 18.87B 7.37B 92.1B 7.3B 7.15B 318B P/E 2026
17.9x
P/E 2027 * 26.3x
Enterprise Value 187B 1.95B 1.71B 1.59B 1.46B 2.74B 2.78B 18.87B 7.37B 92.1B 7.3B 7.15B 318B EV / Sales 2026
5.23x
EV / Sales 2027 * 7.53x
Free-Float
26.39%
Yield 2026 *
-
Yield 2027 * 0.16%
1 day+6.51%
1 week-0.86%
Current month+0.03%
1 month+2.60%
3 months+48.86%
6 months+51.84%
Current year+42.57%
1 week 2,455
Extreme 2455
2,664.85
1 month 2,455
Extreme 2455
2,700
Current year 1,502.45
Extreme 1502.45
2,700
1 year 1,502.45
Extreme 1502.45
2,700
3 years 849.25
Extreme 849.25
2,700
5 years 575
Extreme 575
2,700
10 years 180
Extreme 180
2,700
Manager TitleAgeSince
Chief Executive Officer 71 28/03/2015
Director of Finance/CFO - 19/02/2016
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 27/01/2010
Director/Board Member - 05/11/2025
Director/Board Member 71 28/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
+6.51%-0.86%+27.98%+207.09% 1.95B
+1.63%+0.76%+15.81%+73.69% 48.36B
+1.52%+2.21%+61.55%+111.64% 35.8B
-0.52%-2.66%-10.74%+19.78% 11.83B
-0.02%-3.54%+13.08%+70.64% 11.48B
-0.28%-0.37%+37.53%+142.08% 9.01B
+0.18%+1.77%+47.40%-8.43% 6.99B
+1.72%-0.84%+13.21%+33.82% 6.7B
+0.30%-1.85%+2.50%+167.29% 6.42B
-7.92%-13.61%-33.87%-3.30% 5.3B
Average +0.30%-2.48%+17.45%+81.43% 14.38B
Weighted average by Cap. +0.74%-0.52%+25.31%+80.04%

Financials

2026 2027 *
Net sales 21.28B 221M 194M 180M 166M 311M 316M 2.14B 837M 10.46B 829M 812M 36.17B 24.88B 258M 227M 211M 194M 364M 369M 2.51B 979M 12.23B 970M 949M 42.29B
Net income 6.16B 63.99M 56.2M 52.26M 47.96M 90.11M 91.5M 621M 242M 3.03B 240M 235M 10.47B 7.13B 74.01M 65.01M 60.45M 55.47M 104M 106M 718M 280M 3.5B 278M 272M 12.12B
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
3,966
Date Price Change Volume
27/07/26 2,625.00 +6.51% 12,119
24/07/26 ₹2,464.65 -0.90% 8,465
23/07/26 ₹2,487.15 +0.25% 9,678
22/07/26 ₹2,480.95 -4.84% 9,799
21/07/26 ₹2,607.05 -1.54% 3,049
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,464.65INR
Average target price
2,505.00INR
Spread / Average Target
+1.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPLIPOINT Stock